RCRachel Jorge Dino Cossetti

Rachel Jorge Dino Cossetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachel Jorge Dino Cossetti has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Papiloma nasal invertido: revisão sistemática sobre potencial de malignização e manejo clínico

    by Karina Marques Milhomem de Sousa, Rachel Jorge Dino Cossetti, Gustavo Duarte Rodrigues, Letícia Sá de Brito, Rebeca Clery da Rocha Nogueira, Janiton de Souza Fonseca, Vitória Alvina Ferreira Lima Gomes Weba, Lunna Oliveira Santos Fontes

    O presente estudo caracteriza-se como uma revisão sistemática da literatura, cujo objetivo é investigar a problemática da malignização do Papiloma Nasal Invertido, um tipo de tumor que, inicialmente benigno, pode evoluir para maligno devido a tratamentos inadequados e cuidados insuficientes. Essa transformação pode resultar em diversos tipos de carcinoma, o que reforça a relevância de estudos mais aprofundados sobre o tema. Dada a escassez de pesquisas específicas nessa área, o presente estudo selecionou 19 artigos relevantes, dos quais 6 foram utilizados para a composição dos resultados. Esses artigos foram obtidos em diferentes bases de dados, como PUBMED, SCIELO e BVS, com a restrição de publicação nos últimos cinco anos. Os resultados indicam que, além da eliminação de potenciais fatores de risco, a prevenção, o diagnóstico precoce e o acompanhamento em longo prazo são cruciais para o manejo do Papiloma Nasal Invertido. Destaca-se ainda a alta taxa de recorrência desse tipo de tumor, o que torna o acompanhamento contínuo essencial para minimizar complicações e reduzir a probabilidade de malignização.

  • Open Access

    High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites

    by Plinio da Cunha Leal, Ed Carlos Rey Moura, Rachel Jorge Dino Cossetti, Johnny Ramos Do Nascimento, Izabel Cristina Portela Bogéa Serra, Bruno de Paulo Ribeiro, Andre Álvares Marques Vale, Ana Paula Silva de Azevedo dos Santos, Flavia Raquel Fernandes Do Nascimento, Rioko Kimiko Sakata

    The purpose of this study was to evaluate the effect of gabapentin on Ehrlich tumor growth in Swiss mice, a highly aggressive and inflammatory tumor model. Mice were grouped into sets of 5 animals and treated from days 2 to 8 with gabapentin 30 mg/kg body weight (G30) or 100 mg/kg body weight (G100), or normal sterile saline (control). The mice were euthanized on day 10. Tumor growth, tumoricidal agents and inflammatory cytokines levels were assessed. At day 10, G30 and G100 mice gained weight, but there were no differences in tumor cell count or in ascites volume. In G100, there was a reduction in arginase and an increase in SOD activities. There was an increase in IL-6 and MCP-1 levels, especially in G100, but no alterations in TNF-α. There was no direct evidence of tumor induction by gabapentin. However, the findings suggest that its use modulates immune response to a more effector and less deleterious profile, with increase in activity of anti-oxidant enzymes and in cytokines that favor activation of macrophages, which could improve the general status of the tumor host.


  • Open Access

    Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases

    by Rachel Jorge D Cossetti, Regis Otaviano França Bezerra, Brenda Gumz, Adriana Telles, Frederico P Costa

    Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.